氯沙坦联合罗格列酮对糖尿病肾病患者UAER和C-反应蛋白的影响

Effects of losartan combined with rosiglitazone on UAER and CRP of diabetic nephropathy

目的:观察氯沙坦及联合罗格列酮对糖尿病肾病(DN)患者尿白蛋白排泄率(UAER)和C-反应蛋白(CRP)的影响。方法:将65例2型糖尿病肾病(Mogensen分期Ⅳ期)患者随机分为对照组(30例)和治疗组(35例),在常规降糖治疗的同时,对照组单用氯沙坦治疗;治疗组联合氯沙坦和罗格列酮治疗,疗程共12周,分别观察治疗前后两组UAER和CRP的变化。结果:两组治疗12周后,UAER和CRP水平均较治疗前下降(P<0.05),而治疗组UAER和CRP水平较对照组显著下降(P<0.05)。结论:氯沙坦可降低DN患者UAER和CRP水平,而氯沙坦联合罗格列酮对DN患者UAER和CRP协同作用,具有更明显的疗效。

Objective：To observe the effects of losartan combined with roslglitazone on UAER and CRP of diabetic nephropathy. Methods：65 patients with diabetic nephropathy（Mogensen Ⅳ stage） were randomly divided into control group and treatment group. On the basis of controlling blood sugar,30 patients in control group were treated with losartan 50 mg once a day. Meanwhile,the other 35 patients in treatment group,on the basis of the control group,were treated with msiglitazone 4 mg once a day,with a treatment course of 12 weeks for both groups. The UAER and CRP were deteced before and after treatment. Results：In all eases,the levels of UAER and serum CRP were decreased after treatment with losartan alone or combined with msiglitazone for 12 weeks,the mean UAER was 305.63±46.92 and 281.46±38.55 respectively ;the level of serum CRP was 4.25±0.74 and 3.86±0.81 respectively. Moreover,the values of UAER and serum CRP in treatment group decreased more singnifieantly than those in control group. Conclusion：The losartan combined with msiglitazone has a more prominently effect on diabetic nephropathy than that of losartan alone.